TMD Titan Medical

Titan Announces Q&A Session with Shareholders

Titan Announces Q&A Session with Shareholders

TORONTO, Ontario, March 20, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that management will host a webcast Q&A session on March 27, 2024 at 1:00 p.m. ET in connection with the merger agreement entered into by Titan with Conavi Medical Inc. (“Conavi”), which was announced by press release issued on March 18, 2024. Titan will provide prepared remarks followed by a Q&A session. Paul Cataford, Interim President and CEO and Chien Huang, Chief Financial Officer will attend the session on behalf of Titan.

Shareholders are invited to submit questions in advance of the Q&A session to . Questions will be accepted until March 25, 2024 at 1:00 pm ET. A link to the live audio webcast will be made available on the "Investor Relations" section of the Company’s website,

About Titan Medical

Titan Medical Inc. (TSX: TMD; OTC: TMDIF), a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ontario, has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Titan’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: Titan will hold a Q&A session with its CEO and CFO in attendance..

These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Titan’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Titan’s ability to retain key personnel; its ability to execute on its business plans and strategies; its ability to continue to license some or all its intellectual property to third parties and receive any material consideration and other factors listed in the “Risk Factors” section of Titan’s Annual Information Form for the fiscal year ended December 31, 2022 (which may be viewed at ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.

Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Titan has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Titan cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Titan expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.

Contact



Titan Medical Inc.                                                

Chien Huang                                                        

Chief Financial Officer                                        

                                

###



EN
20/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Titan Medical

 PRESS RELEASE

Titan Provides Update on Planned Merger with Conavi

Titan Provides Update on Planned Merger with Conavi TORONTO, Ontario, April 22, 2024 (GLOBE NEWSWIRE) --  Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to provide this update on its planned merger with Conavi Medical Inc. (“Conavi”) as previously announced on March 18, 2024 (the “Transaction”). As previously announced, Titan has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock transaction. The combined company will foc...

 PRESS RELEASE

Titan Settles Contractual Dispute with Contract Manufacturer

Titan Settles Contractual Dispute with Contract Manufacturer TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that it has entered into a settlement agreement with a contract manufacturer (“Contractor”). Titan has reached a settlement agreement in connection with a dispute with the Contractor. Under the terms of the settlement, Titan has agreed to pay the Contractor an aggregate of US$2 million, with the final payment installment to be made on or before June 24, 2024. Upon receipt of the full US$2 million, the Contractor w...

 PRESS RELEASE

Titan Medical Reports Fiscal Year 2023 Results

Titan Medical Reports Fiscal Year 2023 Results TORONTO, Ontario, March 29, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the fiscal year ended December 31, 2023. Recent Activities: On August 14, 2023, the Company announced the appointment of Dr. Daniel O’Brien, MD, MBA, Ph.D to its Board of Directors.On August 21, 2023, the Company announced a licensing agreement with Auris Health, Inc., a Johnson & Johnson MedTech Company.On October 18, 2023, the Company announced it had changed its auditor from BDO C...

 PRESS RELEASE

Titan Announces Q&A Session with Shareholders

Titan Announces Q&A Session with Shareholders TORONTO, Ontario, March 20, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that management will host a webcast Q&A session on March 27, 2024 at 1:00 p.m. ET in connection with the merger agreement entered into by Titan with Conavi Medical Inc. (“Conavi”), which was announced by press release issued on March 18, 2024. Titan will provide prepared remarks followed by a Q&A session. Paul Cataford, Interim President and CEO and Chien Huang, Chief Financial Officer will attend the session on behalf of Titan. ...

 PRESS RELEASE

Titan Announces Merger Agreement with Conavi

Titan Announces Merger Agreement with Conavi - Merger to create publicly-listed, commercial-stage leader in hybrid intravascular imaging - TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction. The combined company will focus on continuing to commercialize Conavi’s Novasight Hybrid™ System designed to guide common m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch